For instance, as CCL3, CCL4, and CCL5 have been found to be present at the sites of inflammation in RA and MS, inhibiting only a single chemokine will still allow for alternate chemokine ligands to act on the receptors. Here, CCL5 is linked to myeloid sarcoma.